Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party-Reference-Cited by-同舟云学术

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Published:2021-12-22 Issue:1 Volume:6 Page:e676
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Tettero Jesse M.,Freeman Sylvie,Buecklein Veit,Venditti Adriano,Maurillo Luca,Kern Wolfgang,Walter Roland B.,Wood Brent L.,Roumier Christophe,Philippé Jan,Denys Barbara,Jorgensen Jeffrey L.,Bene Marie C.,Lacombe Francis,Plesa Adriana,Guzman Monica L.,Wierzbowska Agnieszka,Czyz Anna,Ngai Lok Lam,Schwarzer Adrian,Bachas Costa,Cloos Jacqueline,Subklewe Marion,Fuering-Buske Michaela,Buccisano Francesco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference75 articles.

1. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.;Chen;J Clin Oncol,2015

2. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.;Buccisano;Leukemia,2006

3. Assessment of minimal residual disease in standard-risk AML.;Ivey;N Engl J Med,2016

4. Association of measurable residual disease with survival outcomes in patients with acute myeloid Leukemia: a systematic review and meta-analysis.;Short;JAMA Oncol,2020

5. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.;Schuurhuis;Blood,2018

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia;Pathology;2024-10

2. Flow Cytometric Assessment of Malignant Hematologic Disorders;Clinics in Laboratory Medicine;2024-09

3. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML);Leukemia;2024-08-21

4. Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach;Frontiers in Oral Health;2024-08-02

5. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08